Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET

Company Participants

Rachel Frank - Associate Director of Investor Relations

Sanj Patel - Chief Executive Officer

Ross Moat - Senior Vice President & Chief Commercial Officer

John Paolini - Senior Vice President & Chief Medical Officer

Mark Ragosa - Senior Vice President & Chief Financial Officer

Conference Call Participants

Anupam Rama - JPMorgan

Paul Choi - Goldman Sachs

Operator

Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Fourth Quarter and Full Year 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Rachel Frank, Head of Investor Relations. Please go ahead.

Rachel Frank

Thank you, operator. Good morning, everyone and thank you for Kiniksa's call to discuss our fourth quarter and full year 2023 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the Investors section.

As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with the introduction. Ross Moat, our Chief Commercial Officer, will provide an update on our ARCALYST commercial execution. John Paolini, our Chief Medical Officer, will review the abiprubart program and recent Phase II data. Then Mark Ragosa, our Chief Financial Officer, will review our fourth quarter and full year 2023 financial results. And finally, Sanj will return for closing remarks and to kick off the Q&A session, for which Eben Tessari, our Chief Operating Officer, will also be on the line.

Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide as well as under the caption Risk Factors contained in our SEC filings. These statements speak only as of the date of this presentation and we undertake no obligation to update such statements, except as required by law.

With that, I will turn it over to Sanj.

Sanj Patel

Thanks, Rachel and good morning, everyone. I'll review our fourth quarter and full year 2023 financial results today.

Consistent execution in both commercial and clinical settings throughout 2023 has put us in a strong position to further advance our business in the year ahead. The ARCALYST commercialization continues to see meaningful growth with Q4 net product revenue of $71.2 million, putting us at $233.2 million for the past year. We're very encouraged with the commercial execution to date which is underscored by growing prescriber adoption and increased duration, as well as continued high patient satisfaction and payer approvals. Moving forward, we remain highly focused on reaching even more patients and driving long-term sustained growth with ARCALYST.